Eli Lilly and Company

Adedoyin David Abraham

Kevin Ronald Condroski

Andrew T Metcalf

Andrew Karl Dilger

Desta Doro Bume

Kaveri Balan Urkalan

Timothy Scott Kercher

Robert Alan Hazlitt

Shane Michael Walls

Andrew Terrance Metcalf

The present invention provides compounds of the formula: for use in the treatment of systemic sclerosis, fibrosis (e.g. pulmonary fibrosis), achondroplasia, thanatophoric dysplasia (e.g. type I), severe achondroplasia with developmental delay and acanthosis(SADDAN), muenke syndrome or cancer.

FGFR3 inhibitor compounds

The present invention provides compounds of the formula: for use in the treatment of systemic sclerosis, fibrosis (e.g. pulmonary fibrosis), achondroplasia, thanatophoric dysplasia (e.g. type I), severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), muenke syndrome or cancer.

Growing community of inventors

Thornton, CO, United States of America

Adedoyin David Abraham